SOPHiA Genetics Q1 2026: Record Revenue, AI Growth

SOPHiA GENETICS reports robust Q1 2026 earnings, with revenue surging 22% to $21.7M, driven by a record 108K genomic analyses and 75.4% adjusted gross margins. Their AI platform, SOPHiA DDM, expands globally, connecting 537 institutions. U.S., APAC, and EMEA volumes surge, with new apps like liquid biopsy driving growth. Net dollar retention hits 117%, churn under 1%. Partnerships with major hospitals and biopharma companies strengthen. The company reaffirms full-year revenue guidance, trims headcount, and maintains strong liquidity. CEO Jurgi Camblong transitions to executive chair, positioning the company for EBITDA breakeven by end of 2026. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f251aa18b04cd265